Developing a new adjuvant for malaria vaccines
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
This study is testing a new ingredient to make malaria vaccines work better, and it's aimed at helping people who need stronger protection against malaria.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10935775 on NIH RePORTER |
What this research studies
This research focuses on creating a glycolipid-based adjuvant called 7DW8-5 to enhance the effectiveness of malaria vaccines. The approach involves using a combination of nucleic acid priming and whole parasite boosting to stimulate the immune response. The research will assess the safety and efficacy of this adjuvant in non-human primates, with the goal of simplifying vaccine formulation and administration. If successful, this could lead to more effective malaria vaccines for human use.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of malaria, particularly in endemic regions.
Not a fit: Patients who are not at risk of malaria or those who have already been vaccinated against malaria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective malaria vaccines, potentially reducing the incidence of malaria in affected populations.
How similar studies have performed: Previous research has shown success with similar adjuvant approaches in enhancing vaccine efficacy, indicating a promising avenue for malaria vaccine development.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Tsuji, Moriya — Columbia University Health Sciences
- Study coordinator: Tsuji, Moriya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.